

RELEVANT EVENT

Grifols, S.A. ("**Grifols**"), as a continuation of the Relevant Event number 187674 dated May 21st 2013, informs that on August 27th the closing of the subscription of the shares of Aradigm Corporation ("**Aradigm**") by Grifols has taken place and, therefore, the exclusive worldwide licence agreement to develop and commercialize PulmaquinTM has become effective, all under the terms and conditions already reported.

In Barcelona, 28 August 2013

Raimon Grifols Roura
Secretary to the Boards of
Directors of Grifols, S.A.